Interim safety analysis of a randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine as first line chemotherapy for metastatic breast cancer (MBC) – The PELICAN study
S. Al-Batran, S. Saupe, A. Kerber, H.J. Lueck, C. Jackisch, M. Untch, M. Schmidt, E. Jager, N. HarbeckVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)70740-7
File:
PDF, 57 KB
english, 2008